INS and type 2 diabetes mellitus: Therefore, the therapeutic targets for T2DM have shifted from simple hypoglycemic drugs (e.g., insulin and acarbose) to drugs suppressing inflammatory factors (such as IL-1 receptors blockade Anakinra and IKKβ-NF-κB inhibition Salsalate) (Donath, 2013).